At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 239 enrolled
Drug / intervention
Bydureon +1 moredrug
Likely dose
Bydureon 2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Double-blind, Parallel-group Study to Evaluate the Effect of BYDUREON Compared With Placebo on 24-hour Glucose Control in Metformin-treated Patients With Type 2 Diabetes
In Brief
A Phase 4 clinical trial evaluating Bydureon and Placebo for Type 2 Diabetes. Completed, enrolled 239 participants across 29 sites.
Detailed Summary
A Randomized, Double-blind, Parallel-group Study to Evaluate the Effect of Bydureon Compared with Placebo on 24-hour Glucose Control in Metformin-treated Patients with Type 2 Diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 2014
Enrollment StartDec 2014
Primary CompletionAug 2015
TodayJul 2026
First PostedNov 11, 2014
Enrollment StartDec 1, 2014
Primary CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 11.6 years ago
Interventions
Bydureondrug
Once weekly injection of 2mg bydureon (extended release exenatide) for 10 weeks.
Placebodrug
Placebo